Zdrowie i gospodarka · 08/06/2022
FDA Renews Psychopharmacologic Drugs Advisory Committee for 2 Years
The FDA is renewing the Psychopharmacologic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on June 4, 2024.
Zdrowie i gospodarka · 08/06/2022
The FDA is renewing the Psychopharmacologic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on June 4, 2024.